Core Viewpoint - Rosen Law Firm is encouraging investors of Skye Bioscience, Inc. to secure legal counsel before the January 16, 2026 deadline for a securities class action lawsuit related to misleading statements made by the company during the class period from November 4, 2024, to October 3, 2025 [2][6]. Group 1: Class Action Details - Investors who purchased Skye securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 16, 2026 [4]. - The lawsuit alleges that Skye's management made materially false and misleading statements regarding the effectiveness and prospects of its product, nimacimab, leading to investor damages when the truth was revealed [6]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [5]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and success in this area [5].

Core Points - Rosen Law Firm is reminding purchasers of Skye Bioscience, Inc. securities of the January 16, 2026 lead plaintiff deadline for a class action lawsuit [1][2] - Investors who purchased Skye securities between November 4, 2024, and October 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][4] Company Details - The lawsuit alleges that Skye's defendants made materially false and misleading statements regarding the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [4] - The firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [3]

Core Viewpoint - Rosen Law Firm is encouraging investors of Skye Bioscience, Inc. to secure legal counsel before the January 16, 2026 deadline for a class action lawsuit related to securities purchased between November 4, 2024, and October 3, 2025 [1] Group 1: Class Action Details - Investors who purchased Skye securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 16, 2026 [3] - The lawsuit alleges that defendants made materially false and misleading statements regarding Skye's business and the effectiveness of its product, nimacimab, which led to investor damages when the truth was revealed [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/p ...

Summary of Skye's Conference Call Company Overview - **Company**: Skye - **Focus**: Development of CB1 antibody and nimacimab for obesity treatment [1][2] Industry Insights - **Cannabinoid System**: The discussion highlighted the role of the cannabinoid system in energy metabolism and fat storage, referencing the historical context of Rimonabant as a proof of concept for weight loss [3][4] - **Market Dynamics**: The current market is dominated by incretin class drugs, with expectations of price compression affecting GLP-1 medications [44] Core Points and Arguments - **Mechanism of Action**: Skye's nimacimab is designed to be peripherally restricted, avoiding the neuropsychiatric side effects associated with small molecules that penetrate the brain [5][6] - **Preclinical Data**: The company has generated significant preclinical data demonstrating that nimacimab can drive weight loss through a different mechanism than existing drugs, focusing on broader metabolic rewiring [9][10] - **Clinical Findings**: - Phase 2 data indicated that higher doses are necessary for effectiveness, with initial doses being insufficient [14][16] - Combination therapy with tirzepatide showed promising results, with a 30% improvement in weight loss compared to semaglutide [25][26] - The combination therapy maintained weight loss better than semaglutide alone, with only 8-10% weight regain compared to 40% for tirzepatide [12][29] Important but Overlooked Content - **Safety Profile**: The nimacimab has shown a strong safety profile with no neuropsychiatric adverse events reported in clinical trials, which is a significant advantage over previous treatments [6][32] - **Future Development Path**: The company plans to explore higher dosing and combination therapies, aiming for a sweet spot around 600 mg for optimal efficacy [49][50] - **Financial Position**: Skye ended the quarter with approximately $35 million in cash, which is expected to fund upcoming studies and operational needs [59] Next Steps - **Ongoing Studies**: The company is focused on the ongoing extension study to gather more data on dosing and efficacy, with results expected in Q1 [59][41] - **Strategic Focus**: Skye aims to leverage its safety data and preclinical findings to justify higher dosing and explore combination therapies in a competitive market [32][45]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant stock price declines [2][4]. Group 1: Legal Investigation - Faruqi & Faruqi is encouraging investors who suffered losses in Skye to contact them for discussing legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [4]. - On October 6, 2025, Skye announced that nimacimab did not achieve its primary endpoint in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [5]. Group 3: Investor Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of class members [6]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [6]. Group 4: Additional Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Skye's conduct [7].

LOS ANGELES, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Skye Bioscience, Inc., (“Skye” or the "Company") (NASDAQ: SKYE) investors off a class action on behalf of investors that bought securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”). Skye investors have until January 16, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal r ...

Core Points - Rosen Law Firm is reminding purchasers of Skye Bioscience, Inc. securities of the lead plaintiff deadline for a class action lawsuit, which is January 16, 2026 [1] - Investors who purchased Skye securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3] Case Details - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Skye's business and prospects, particularly concerning the effectiveness of nimacimab [5] - Specific claims include that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [5] - The lawsuit asserts that when the true details became known, investors suffered damages [5] Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy of its lead product candidate, nimacimab, during the class period from November 4, 2024, to October 3, 2025 [1] Company Overview - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on developing treatments for obesity and metabolic diseases [1] Legal Proceedings - The lawsuit claims that Skye failed to disclose that the efficacy of nimacimab was lower than represented, leading to an overstatement of the drug's clinical and commercial potential [1] - Investors who purchased Skye securities during the class period have until January 16, 2026, to seek appointment as lead plaintiff [1] Stock Performance - Following the announcement of topline data from a Phase 2a study on October 6, 2025, which revealed that the primary endpoint of an 8% weight loss difference compared to placebo was not met, Skye's stock price fell by $2.85 per share, or 60%, closing at $1.90 [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Skye Bioscience, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - The Class Period for the Skye Bioscience securities is from November 4, 2024, to October 3, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its performance in this area [3]. Group 3: Case Allegations - The lawsuit alleges that Skye Bioscience made materially false and misleading statements regarding its business and the effectiveness of its product, nimacimab [4]. - Specific claims include that nimacimab was less effective than represented, and its clinical and commercial prospects were overstated [4]. - The lawsuit claims that investors suffered damages when the true details about the product were revealed [4].